MIS barriers and corresponding mission governance actions to which actors in the mission arena are committed. od Joeri Wesseling (16819641)

Teme:

Overview of strength and weaknesses of the MIS approach. od Joeri Wesseling (16819641)

Teme:

Overview of interviewees. od Joeri Wesseling (16819641)

Teme:

Primers of this study. od Shuang Li (146392)

Teme:

Agarose gel electrophoresis results of PCR products. od Shuang Li (146392)

Teme:

The degradation of PNP by <i>P</i>. <i>putida</i> DLL-E4, DLL-Δ<i>crc</i>, DLL-Δ<i>crc</i>Y, and DLL-Δ<i>crcZ</i>. od Shuang Li (146392)

Teme:

The growth of <i>P</i>. <i>putida</i> DLL-E4, DLL-Δ<i>crc</i>, DLL-Δ<i>crcY</i>, and DLL-Δ<i>crcZ</i> on LB medium. od Shuang Li (146392)

Teme:

Spatial distribution of overall non-carcinogenic risk (HI) for (a) infants, (b) Children, (c) adult females, and (d) adult males posed by potential harmful substances of groundwate... od Shanhu Xiao (22226759)

Development of immune factors over visits in the AAF and AAF-syn treatment group as (A) scores and (B) loadings. od Diana M. Hendrickx (1507435)

Results of comparing visits within allergy groups using linear mixed models and post hoc analysis. od Diana M. Hendrickx (1507435)

Results of comparing allergy groups within visits using linear mixed models and post hoc analysis. od Diana M. Hendrickx (1507435)

Development of immune factors over visits in the AAF-syn treatment group as (A) scores and (B) loadings when using the AAF treatment group as a reference. od Diana M. Hendrickx (1507435)

Results of comparing treatment groups within visits using linear mixed models and post hoc analysis. od Diana M. Hendrickx (1507435)

Proteins with at least one significant difference (adjusted p-value ≤ 0.05) between visits within allergy groups as determined by linear mixed models and post hoc analysis. od Diana M. Hendrickx (1507435)

Results of comparing visits within treatment groups using linear mixed models and post hoc analysis. od Diana M. Hendrickx (1507435)

Proteins with at least one significant difference (adjusted p-value ≤ 0.05) between visits within treatment groups as determined by linear mixed models and post hoc analysis. od Diana M. Hendrickx (1507435)

KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between treatment groups within visits as determ... od Diana M. Hendrickx (1507435)

Results of comparing treatment groups within visits using KEGG pathway enrichment in ConsensusPathDB. od Diana M. Hendrickx (1507435)

Results of comparing allergy groups within visits using KEGG pathway enrichment in ConsensusPathDB. od Diana M. Hendrickx (1507435)

KEGG pathways (with at least 4 measured proteins) that have at least one significant difference (adjusted p-value (q-value) ≤ 0.05) between visits within treatment groups as determ... od Diana M. Hendrickx (1507435)